AbbVie Sues HHS Over Medicare Price Controls on Botox Under Inflation Reduction Act 
Xiaomi EV Deliveries Surpass 600,000 Units as SU7 and YU7 Drive Strong Growth 
ByteDance Advances AI Chip Development With Samsung Manufacturing Talks 
Sachem Head Boosts Warner Bros. Discovery Stake Amid Netflix Deal and Paramount Bid 
Gates Foundation Denies Financial Ties to Jeffrey Epstein Following DOJ Email Release 
ANZ Shares Hit Record High After Strong Q1 Profit and Cost-Cutting Gains 
U.S. Judge Allows Jeffrey Epstein Sex Trafficking Lawsuit Against Bank of America to Proceed 
Spirit Airlines Seeks Court Approval to Auction 20 Airbus A320/A321 Aircraft Amid Bankruptcy 
Westpac (ASX: WBC) Q1 Profit Rises 6% as Lending Growth and Treasury Income Strengthen Earnings 
Paramount Skydance Appoints Rene Augustine as SVP of Global Public Policy Amid Warner Bros Takeover Battle 
Vale Reports $3.8 Billion Q4 Net Loss Amid Nickel Asset Impairment and Samarco Provisions 
Valero Energy Expands Venezuelan Crude Imports as U.S. Sanctions Ease 
GE Aerospace Expands Singapore Engine Repair Hub with Automation and AI to Tackle Aviation Bottlenecks 
Senators Urge CFIUS Review of UAE Investment in Trump-Linked Crypto Firm World Liberty Financial 
Anduril Eyes $60 Billion Valuation in New Funding Round to Expand Defense Manufacturing and Autonomous Fighter Jet Development 
U.S. Commerce Department Reaches $252 Million Settlement With Applied Materials Over China Exports 
Converse Cuts Corporate Jobs as Nike Restructures to Revive Sales Growth 
SINGAPORE, April 17, 2018 -- ASLAN Pharmaceuticals (ASLAN) (6497.TT), a clinical-stage biopharmaceutical company targeting cancers that are both highly prevalent in Asia and orphan indications in the United States and Europe, today announced the presentation of new data from a study of the use of varlitinib in hepatocellular carcinoma (HCC) at the American Association for Cancer Research (AACR) 2018 Annual Meeting in Chicago, Illinois.
| Details of the poster are as below: | ||
| Session: | Experimental and Molecular Therapeutics | |
| Poster #: | 3992 / 26 | |
| Section: | 41 | |
| Title: | Varlitinib demonstrates tumor regression and vessel normalization in ErbB-dependent and mutated beta-catenin hepatocellular carcinoma patient-derived xenograft model | |
The pre-clinical study was conducted in collaboration with the National Cancer Centre Singapore (NCCS) and was led by Professor The Huynh Hung, Principal Investigator at NCCS’ Laboratory of Molecular Endocrinology. The study was designed to demonstrate the efficacy of varlitinib in HCC patient-derived xenograft (PDX) models and to study the molecular mechanisms of varlitinib-mediated tumor suppression and its anti-angiogenic potential. In addition, the study sought to identify gene signatures associated with efficacy of varlitinib by transcriptome and gene expression analyses.
About varlitinib (ASLAN001)
Varlitinib (ASLAN001) is a highly potent, oral, reversible, small molecule pan-HER inhibitor that targets the human epidermal growth factor receptors HER1, HER2 and HER4. These receptors can be mutated or overexpressed in many tumors, which can cause excessive proliferative activity and uncontrolled growth. Therefore, by inhibiting the activation of the HER receptors, varlitinib could inhibit proliferation and control tumor growth. Varlitinib is currently being studied in gastric, biliary tract, breast and colorectal cancers. Varlitinib has been granted orphan drug designation in the United States for gastric cancer and cholangiocarcinoma, a sub-type of biliary tract cancer, and was awarded orphan drug designation for the treatment of biliary tract cancer by the Ministry of Food and Drug Safety in South Korea.
About ASLAN Pharmaceuticals
ASLAN Pharmaceuticals (ASLAN, 6497.TT) is a clinical-stage oncology-focused biopharmaceutical company developing novel therapeutics for global markets. ASLAN targets diseases that are both highly prevalent in Asia and orphan indications in the United States and Europe. Led by a senior management team with extensive experience in global and regional development and commercialization, ASLAN is headquartered in Singapore and has offices in Taiwan and China. ASLAN’s portfolio is comprised of four product candidates which target validated growth pathways applied to new patient segments, novel immune checkpoints and novel cancer metabolic pathways. ASLAN’s partners include Array BioPharma, Bristol-Myers Squibb, Almirall and CSL. For additional information please visit www.aslanpharma.com.
Media and IR contacts Chris Fang ASLAN Pharmaceuticals Tel: +886 2 2758 3333 Email: [email protected] Emma Thompson / Stephanie Tan Spurwing Communications Tel: +65 6340 7287 Email: [email protected] Robert H Uhl Westwicke Partners Tel: +1 858 356 5932 Email: [email protected]
